How Has the Sickle Cell Disease Treatment Market Size Evolved in Recent Years?
The sickle cell disease treatment market has seen considerable growth due to a variety of factors.
• There has been a swift expansion in the market size for treating sickle cell diseases in the past few years. The market size is projected to rise from $2.95 billion in 2024 to $3.54 billion in 2025, with a compound annual growth rate (CAGR) of 19.7%.
Factors contributing to the substantial growth during the historic period include increased knowledge about the disease, the use of blood transfusions, pain management strategies, and hydroxyurea therapy.
What Are The Predictions for The Sickle Cell Disease Treatment Market in the Coming Years?
The sickle cell disease treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for treatment of sickle cell disease is predicted to experience a speedy expansion in the forthcoming years, reaching $6.8 billion in 2029, with a compound annual growth rate (CAGR) of 17.7%.
This upsurge during the projection period can be credited to elements like gene editing and therapy, the development of new medications, utilization of telemedicine and remote monitoring, along with worldwide health initiatives. Key trends predicted for this timeframe encompass curing therapies, alternative methods for pain management, international collaborations, and increased focus on patient advocacy and engagement.
Which Drivers Are Accelerating Growth In The Sickle Cell Disease Treatment Market?
The expected surge in blood transfusion requirements is poised to spur the expansion of the market for sickle cell disease treatments. Blood transfusion, a medical practice involving the transfer of blood or blood products from a donor to a recipient, plays an integral role in managing sickle cell disease. This procedure aids in enhancing the oxygen-carrying ability of blood and alleviates complications tied to vaso-occlusion. As reported by the Mid-Atlantic Long-Term Care, a company in the USA that offers specialist 24-hour triage on-call assistance, around 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma are required daily in the USA as of January 2022. As a result, the growing need for blood transfusion is stimulating the sickle cell disease treatment market's growth. For the Sickle Cell Disease Treatment Market, a key driving factor is the rise in blood and bone marrow transplantation, leading to advancements in treatments for this disease. The process entails the substitution of unwell blood-forming cells with healthy ones, making it highly beneficial in curing sickle cell diseases and cancers. The goal of a bone marrow transplant is to supplant unhealthy bone marrow, which has been treated to discard the defective cells, with healthy marrow cells. These replacement cells can be either autologous (from the patient's body) or allogenic (from a donor's body). The National Transplant Organization (ONT) in Spain reported in June 2024 that Spain registered an 8% increase in its Bone Marrow Donor Registry, reaching a total of 23,686 donors in 2023, and performed a record 3,717 hematopoietic stem cell transplants, equivalent to 77.4 transplants per million population. This rising trend in blood and bone marrow transplants is projected to invigorate the sickle cell disease treatment market.
What Are The Core Segments Of The Global Sickle Cell Disease Treatment Market?
The sickle cell disease treatment market covered in this report is segmented –
1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types
3) By Route Of Administration: Oral, Parenteral
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion
2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant
Pre-Book The Sickle Cell Disease Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Sickle Cell Disease Treatment Market?
Leading firms in the market for sickle cell disease treatments are striving to create new oral suspension medicines to enhance patient compliance, augment the effectiveness of the drug, and offer easier treatment methods, particularly for pediatric and elderly patients. Oral suspension drugs are medications in liquid form that contain solid particles, designed to simplify the swallowing process, especially for children or individuals having difficulty with pill ingestion. For example, in March 2024, a company originating from India, Akums Drugs and Pharmaceuticals Ltd., specializing in pharmaceutical preparation manufacturing, introduced a Hydroxyurea oral suspension that remains stable at room temperature. This affordable, room-temperature-stable sickle cell disease treatment aims to boost accessibility in India. With a cost less than 1% of imported equivalents, it provides exact dosage administration via oral syringes, which benefits patients of all ages without the necessity for cold storage.
Who Are the Key Players In The Sickle Cell Disease Treatment Market?
Major companies operating in the sickle cell disease treatment market are:
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Johnson & Johnson Private Limited
• Merck & Co Inc.
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Silver Lake Research Corporation0.45
• Global Blood Therapeutics Inc.
• Acceleron Pharma Inc.
• Sangamo Therapeutics Inc.
• Medunik USA Inc.
• Zydus Cadila Healthcare Ltd.
• Graphite Bio Inc.
• Addmedica
• Emmaus Medical Inc.
• Bluebird bio Inc.
• CRISPR Therapeutics AG
• GlycoMimetics Inc.
• Arena Pharmaceuticals Inc.
• Mast Therapeutics Inc.
What Are The Regional Insights Into The Sickle Cell Disease Treatment Market?
North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
